相关实验视频

Updated: Jul 28, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

沃尔登斯特罗姆巨型球蛋白血症的前线管理与化疗免疫疗法

Prashant Kapoor¹, Jonas Paludo¹, Jithma P Abeykoon¹

¹Division of Hematology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.

Hematology/oncology clinics of North America

|May 28, 2023

概括

化疗免疫疗法 (CIT),特别是达穆斯丁-瑞图西马布 (BR),仍然是沃尔登斯特罗姆巨型球蛋白血症 (WM) 的相关治疗方法. BR提供了疗效和耐受性,作为评估新的WM疗法的基准.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床试验临床试验

背景情况:

沃尔登斯特罗姆巨型球蛋白血症 (WM) 是一种CD20+B细胞恶性瘤.
化学免疫疗法 (CIT) 和基于布鲁顿氨酸激酶抑制剂 (BTKi) 的疗法是WM的主要治疗策略.
班达穆斯丁-利图西马布 (BR) 已成为一种非常有效的CIT疗法,用于以前未接受过治疗的WM患者.

研究的目的:

审查CIT的作用和疗效,特别是bendamustine-rituximab (BR) 疗法,用于治疗沃尔登斯特罗姆巨球蛋白血症 (WM).
将BR与其他已知WM治疗方法进行比较,并讨论其在临床试验中作为对照组的潜力.

主要方法:

审查现有的临床试验数据和对WM中CIT和BTKi疗法的回顾性研究.
对不同WM治疗方案的疗效,安全性和耐受性概况进行比较分析.
评估BR作为未来新型WM药物的临床试验中的比较组.

主要成果:

与WM中的R-CHOP相比,Bendamustine-rituximab (BR) 显示出更高的疗效和更好的安全性.
BR是一种广泛采用的前线治疗,用于以前没有接受过治疗的WM患者.
虽然直接比较是有限的,但BR似乎比甲,利图西马布和环胺 (DRC) 更强大,并且在MYD88突变的WM中显示了与连续易布鲁替尼比较的结果.

结论:

化疗免疫疗法 (CIT),特别是达穆斯丁-利图西马布 (BR) 疗法,仍然是沃尔登斯特罗姆巨型球蛋白血症 (WM) 的重要和有效的治疗选择.
由于BR的已知疗效,耐受性和成本效益,使其成为在WM临床试验中评估新型向药物的合适对照组.
虽然BTKi抑制剂提供了一个替代品,但无论MYD88突变状态如何,BR的有效性都增加了其在WM管理中的多功能性.

关键词:

化剂是一种化剂.在 IgM 淋巴细胞质细胞淋巴瘤.治疗时间有限的治疗.单克隆抗体是一种单克隆抗体.纯氨酸类型的类似物.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.